-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the statistics of choice, as of October 26, 76 companies in the pharmaceutical manufacturing industry have issued three quarterly reports
.
On the whole, the performance polarization is obvious.
Some companies, such as Jiaying Pharmaceutical, Northeast Pharmaceutical, Taiji Group, Harbin Sanlian, etc.
, have soared their net profit in the first three quarters, increasing by more than 1,000% year-on-year.
Profits have fallen sharply, and some companies have even suffered losses
.
While the three quarterly reports were disclosed, the research and development expenses of various pharmaceutical companies in the first three quarters have also been exposed
.
According to regulations, listed companies must complete the third quarter report performance disclosure before October 31.
Although there are still pharmaceutical companies that have not released the third quarter report yet, judging from the listed pharmaceutical companies that have disclosed their third quarter financial reports, many pharmaceutical companies have invested in research and development.
Over 100 million yuan, the research and development expenses of pharmaceutical companies such as Hengrui and Fuxing even exceed 3 billion yuan
.
According to Hengrui Pharmaceutical’s 2021 third quarter report released on October 19, Hengrui Pharmaceutical’s R&D investment continued to increase this year.
The R&D expenditure in the first three quarters reached 4.
142 billion yuan, of which R&D expenses in the third quarter reached 1.
56 billion yuan, accounting for revenue.
The proportion exceeds 20%, a record high
.
Sustained high-intensity R&D investment has brought fruitful innovation results to the company
.
Since the beginning of this year, Hengrui Medicine has submitted 31 IND applications and has obtained 23 approvals; among them, there are already 5 NDA approvals in the first half of the year, which is close to 2020
.
Carrelizumab combined with apatinib in the treatment of high-risk chemotherapy-resistant or recurrent gestational trophoblastic tumors and other 4 new research results appeared on the "Lancet Tumor", "Journal of the American Medical Association" and "Journal of Thoracic Oncology" Other international journals have also proved that the company's original innovative drug strength has been recognized by the international academic community again
.
Fosun Pharma announced its operating results for the first three quarters on the evening of October 26
.
The financial report shows that in the first three quarters of 2021, Fosun Pharma invested 3.
151 billion yuan in R&D, a year-on-year increase of 15.
46%
.
Among them, research and development expenses were 2.
414 billion yuan, a year-on-year increase of 28.
54%
.
With high R&D investment, Fosun Pharma’s innovation continues
.
The company stated in its financial report that after its CAR-T treatment product "Yikaida" was launched, it has actively explored innovative payment models and has been included in the payment range of "Huiminbao" in Changsha, Suzhou and other cities to increase the product's accessibility.
The product’s second indication (used to treat relapsed or refractory indolent non-Hodgkin’s lymphoma (r/r iNHL) after receiving second-line or above systemic treatment) will be launched in 2021.
In August, it was included in the breakthrough therapeutic drug program by the National Food and Drug Administration
.
At the same time, Fosun Pharma’s R&D and commercialization of macromolecular drugs is also steadily advancing
.
Domestic medical device giant Mindray Medical is not soft on R&D investment, according to the company’s 2021 In the third quarter report, Mindray Medical’s R&D investment in the first three quarters reached 1.
79 billion yuan, and the R&D expense ratio was 8.
40%
.
Soochow Securities released a research report that Mindray Medical continued to increase R&D investment since 2015, and the R&D expense ratio remained around 10% for a long time.
Continue to increase research and development costs to lay a foundation for future growth for high-end products
.
In the third quarter of this year, Mindray Medical launched a new platform Hybase V8 (CE), MC-80 fully automated cell morphology analyzer, and integrated ultrasound application solutions.
New products such as "Nuwa R7" are planned
.
In addition to the above companies, many pharmaceutical companies such as Yuandong Biology and Frontier Biology have invested more than 100 million yuan in R&D in the first three quarters of this year, and their share of revenue is increasing
.
Industry, R&D investment has always been the main task for pharmaceutical companies to maintain their competitiveness
.
In recent years, as various policies have highlighted the importance of R&D, China’s pharmaceutical industry’s long-standing "sales rather than R&D" situation is expected to improve
.
The industry pointed out that it will continue The R&D investment and the reserve of high-end R&D personnel will be the key for future innovative pharmaceutical companies to stand out and embark on the international stage
.
.
On the whole, the performance polarization is obvious.
Some companies, such as Jiaying Pharmaceutical, Northeast Pharmaceutical, Taiji Group, Harbin Sanlian, etc.
, have soared their net profit in the first three quarters, increasing by more than 1,000% year-on-year.
Profits have fallen sharply, and some companies have even suffered losses
.
While the three quarterly reports were disclosed, the research and development expenses of various pharmaceutical companies in the first three quarters have also been exposed
.
According to regulations, listed companies must complete the third quarter report performance disclosure before October 31.
Although there are still pharmaceutical companies that have not released the third quarter report yet, judging from the listed pharmaceutical companies that have disclosed their third quarter financial reports, many pharmaceutical companies have invested in research and development.
Over 100 million yuan, the research and development expenses of pharmaceutical companies such as Hengrui and Fuxing even exceed 3 billion yuan
.
According to Hengrui Pharmaceutical’s 2021 third quarter report released on October 19, Hengrui Pharmaceutical’s R&D investment continued to increase this year.
The R&D expenditure in the first three quarters reached 4.
142 billion yuan, of which R&D expenses in the third quarter reached 1.
56 billion yuan, accounting for revenue.
The proportion exceeds 20%, a record high
.
Sustained high-intensity R&D investment has brought fruitful innovation results to the company
.
Since the beginning of this year, Hengrui Medicine has submitted 31 IND applications and has obtained 23 approvals; among them, there are already 5 NDA approvals in the first half of the year, which is close to 2020
.
Carrelizumab combined with apatinib in the treatment of high-risk chemotherapy-resistant or recurrent gestational trophoblastic tumors and other 4 new research results appeared on the "Lancet Tumor", "Journal of the American Medical Association" and "Journal of Thoracic Oncology" Other international journals have also proved that the company's original innovative drug strength has been recognized by the international academic community again
.
Fosun Pharma announced its operating results for the first three quarters on the evening of October 26
.
The financial report shows that in the first three quarters of 2021, Fosun Pharma invested 3.
151 billion yuan in R&D, a year-on-year increase of 15.
46%
.
Among them, research and development expenses were 2.
414 billion yuan, a year-on-year increase of 28.
54%
.
With high R&D investment, Fosun Pharma’s innovation continues
.
The company stated in its financial report that after its CAR-T treatment product "Yikaida" was launched, it has actively explored innovative payment models and has been included in the payment range of "Huiminbao" in Changsha, Suzhou and other cities to increase the product's accessibility.
The product’s second indication (used to treat relapsed or refractory indolent non-Hodgkin’s lymphoma (r/r iNHL) after receiving second-line or above systemic treatment) will be launched in 2021.
In August, it was included in the breakthrough therapeutic drug program by the National Food and Drug Administration
.
At the same time, Fosun Pharma’s R&D and commercialization of macromolecular drugs is also steadily advancing
.
Domestic medical device giant Mindray Medical is not soft on R&D investment, according to the company’s 2021 In the third quarter report, Mindray Medical’s R&D investment in the first three quarters reached 1.
79 billion yuan, and the R&D expense ratio was 8.
40%
.
Soochow Securities released a research report that Mindray Medical continued to increase R&D investment since 2015, and the R&D expense ratio remained around 10% for a long time.
Continue to increase research and development costs to lay a foundation for future growth for high-end products
.
In the third quarter of this year, Mindray Medical launched a new platform Hybase V8 (CE), MC-80 fully automated cell morphology analyzer, and integrated ultrasound application solutions.
New products such as "Nuwa R7" are planned
.
In addition to the above companies, many pharmaceutical companies such as Yuandong Biology and Frontier Biology have invested more than 100 million yuan in R&D in the first three quarters of this year, and their share of revenue is increasing
.
Industry, R&D investment has always been the main task for pharmaceutical companies to maintain their competitiveness
.
In recent years, as various policies have highlighted the importance of R&D, China’s pharmaceutical industry’s long-standing "sales rather than R&D" situation is expected to improve
.
The industry pointed out that it will continue The R&D investment and the reserve of high-end R&D personnel will be the key for future innovative pharmaceutical companies to stand out and embark on the international stage
.
